Depression psychotherapies have been studied using hundreds of randomized controlled trials and dozens of meta-analyses, but their findings are not consistently supportive of a single conclusion. Can the disparities be attributed to specific meta-analytic choices, or do the majority of analytic strategies result in the same conclusion?
These discrepancies will be addressed by constructing a multiverse meta-analysis that encompasses all potential meta-analyses and applies all statistical methods.
We performed a comprehensive search across four bibliographic databases—PubMed, EMBASE, PsycINFO, and the Cochrane Register of Controlled Trials—to identify studies published until the beginning of January 2022. Our analysis incorporated every randomized controlled trial, irrespective of psychotherapy type, target group, intervention format, control condition, or diagnosis, that compared psychotherapies to control groups. We cataloged all meta-analyses potentially arising from the combinations of these criteria and then evaluated the associated pooled effect sizes, employing fixed-effect, random-effects, 3-level, and robust variance estimation techniques.
Uniform and PET-PEESE (precision-effect test and precision-effect estimate with standard error) meta-analytical models were a crucial component of the study. As part of the study's pre-emptive measures, this study was preregistered, and this link provides access to the registration: https//doi.org/101136/bmjopen-2021-050197.
A comprehensive review of 21,563 records yielded 3,584 full-text articles for further analysis; ultimately, 415 studies met inclusion criteria, encompassing 1,206 effect sizes and involving 71,454 participants. Considering all possible pairings of inclusion criteria and meta-analytic approaches, we determined 4281 distinct meta-analyses. Hedges' g, the average summary effect size, was derived from these meta-analyses.
With a medium effect size of 0.56, the values demonstrated a range of variation.
Numerical values extend between negative sixty-six and two hundred fifty-one. Across the board, 90% of these meta-analyses pointed to a clinically relevant effect size.
Psychotherapies' effectiveness against depression, as evidenced by a meta-analysis that explored different realities, proved remarkably robust. It is noteworthy that meta-analyses containing studies with a high risk of bias, contrasting the intervention with wait-list controls, and lacking adjustments for publication bias, yielded greater effect sizes.
A multiverse meta-analysis highlighted the uniform robustness of psychotherapies' effectiveness in treating depression. Substantially, meta-analyses including studies with a high risk of bias, when comparing the intervention to a wait-list control, and without accounting for publication bias, yielded larger effect sizes.
Cellular immunotherapies for cancer employ tumor-specific T cells in high numbers to enhance the patient's immune system's ability to combat the disease. The technique of CAR therapy harnesses genetic engineering to redirect peripheral T cells toward tumor cells, resulting in remarkable effectiveness in the treatment of blood cancers. Unfortunately, CAR-T cell therapies demonstrate limited effectiveness against solid tumors, due to the presence of several resistance mechanisms. Immune cell function is hampered by a unique metabolic landscape within the tumor microenvironment, as demonstrated by our work and others'. Subsequently, the altered differentiation of T cells within tumor microenvironments leads to defects in mitochondrial biogenesis, resulting in profound cell-intrinsic metabolic impairments. While studies have indicated that enhancements in mitochondrial biogenesis can improve murine T cell receptor (TCR) transgenic cells, our investigation sought to determine the feasibility of a metabolic reprogramming approach for boosting human CAR-T cell function.
NSG mice bearing A549 tumors received infusions of anti-EGFR CAR-T cells. Tumor-infiltrating lymphocytes were examined for indications of exhaustion and metabolic dysfunction. Lentiviruses transport both copies of PPAR-gamma coactivator 1 (PGC-1) in tandem with PGC-1.
NT-PGC-1 constructs were employed to co-transduce T cells alongside anti-EGFR CAR lentiviruses. selleck chemicals In vitro, metabolic analysis was performed employing flow cytometry and Seahorse analysis, alongside RNA sequencing. Lastly, A549-carrying NSG mice received therapeutic treatment with either PGC-1 or NT-PGC-1 anti-EGFR CAR-T cells. We examined the variations in tumor-infiltrating CAR-T cells, contingent upon the co-expression of PGC-1.
We have found, in this investigation, that an engineered PGC-1, impervious to inhibition, can metabolically reprogram human CAR-T cells. Transcriptomic characterization of CAR-T cells engineered with PGC-1 displayed a clear induction of mitochondrial biogenesis, yet also a corresponding enhancement of programs vital for the effector functions of these cells. A treatment protocol involving these cells in immunodeficient animals bearing human solid tumors resulted in a noteworthy enhancement of in vivo efficacy. selleck chemicals Whereas the full-length PGC-1 protein led to positive outcomes, a truncated version, NT-PGC-1, was not as successful in improving in vivo results.
Our research on immunomodulatory treatments further underscores the significance of metabolic reprogramming, and highlights the potential of genes like PGC-1 as promising additions to cell therapies for solid tumors, potentially combined with chimeric receptors or TCRs.
Our data are consistent with a role of metabolic reprogramming in the immunological effects of treatments, and genes like PGC-1 are attractive targets for inclusion in cell therapy cargos designed for solid tumors, in combination with chimeric receptors or T-cell receptors.
Primary and secondary resistance poses a substantial barrier to progress in cancer immunotherapy. Subsequently, a superior understanding of the underlying mechanisms related to immunotherapy resistance is vital to improving treatment outcomes.
In this study, two mouse models with a resistance to therapeutic vaccine-induced tumor regression were examined. Therapeutic interventions, coupled with high-dimensional flow cytometry, facilitate the exploration of the tumor microenvironment.
Immunological factors behind immunotherapy resistance were pinpointed by the designated settings.
The immune infiltrate within the tumor, examined at both early and late regression stages, demonstrated a shift from macrophages characteristic of tumor rejection to those associated with tumor promotion. A sharp and rapid decline of tumor-infiltrating T cells was seen in conjunction with the concert. CD163 was subtly yet significantly observed in perturbation-based research.
The singular macrophage population with a high expression level of various tumor-promoting macrophage markers and a functional anti-inflammatory transcriptomic profile is responsible, and not any other macrophage population. selleck chemicals In-depth studies highlighted their accumulation at the tumor's invasive margins, displaying greater resistance to CSF1R inhibition than other macrophage populations.
Heme oxygenase-1's function as an underlying mechanism of immunotherapy resistance was corroborated by multiple studies. CD163's transcriptomic signature.
Macrophages are highly comparable to human monocyte/macrophage populations, which indicates their status as potential targets to enhance immunotherapy's efficacy.
For the purposes of this study, a limited number of CD163 cells were investigated.
It has been determined that tissue-resident macrophages are the causative agents for primary and secondary resistance against T-cell-based immunotherapies. In the presence of these CD163 molecules,
Immune checkpoint blockade therapies frequently face resistance from M2 macrophages expressing the Csf1r. Pinpointing the underlying mechanisms behind this resistance is essential to strategically target these macrophages and improve the effectiveness of immunotherapy.
This research work established that a small quantity of CD163hi tissue-resident macrophages are the drivers for both primary and secondary resistance to immunotherapies that depend on T cells. Though resistant to CSF1R-targeted therapies, the in-depth characterization of the underlying mechanisms driving immunotherapy resistance in CD163hi M2 macrophages paves the way for therapeutic interventions aimed at overcoming this resistance.
Myeloid-derived suppressor cells (MDSCs), a heterogeneous group of cells situated in the tumor microenvironment, function to suppress anti-tumor immunity. Patients with cancer experiencing poor clinical outcomes frequently demonstrate an increase in different MDSC subpopulations. The deficiency of lysosomal acid lipase (LAL), an essential enzyme in the metabolic pathway of neutral lipids, results in the differentiation of myeloid lineage cells into MDSCs in mice. These sentences, needing ten iterations of reformulation, must exhibit original and distinct grammatical structures.
MDSCs impede immune surveillance and concurrently stimulate cancer cell proliferation and invasion. Delineating the intricate mechanisms behind MDSC genesis will empower us to better identify and predict the onset of cancer, while simultaneously hindering its expansion and spread.
Single-cell RNA sequencing (scRNA-seq) provided a method for differentiating the inherent molecular and cellular characteristics between normal and abnormal cells.
Ly6G, a product of bone marrow development.
Myeloid cell populations of mice. Researchers analyzed LAL expression and metabolic pathways in diverse myeloid subsets of blood samples from patients with non-small cell lung cancer (NSCLC) employing flow cytometry. An investigation into the profiles of myeloid cell populations in NSCLC patients was carried out before and after treatment with programmed death-1 (PD-1) immunotherapy.
Single-cell RNA sequencing, abbreviated as scRNA-seq, is an important technique
CD11b
Ly6G
MDSCs were found to comprise two distinct clusters, characterized by differential gene expression profiles, and underwent a substantial metabolic alteration, favoring glucose consumption and heightened reactive oxygen species (ROS) generation.